IMR Press / EJGO / Volume 27 / Issue 4 / pii/2006183

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Distinguished Expert Series

Vaccination against human genital papillomaviruses. More than a hypothesis

Show Less
1 National Tumor Institute, Milan, Italy
2 Regina Elena Cancer Institute, Rome, Italy
Eur. J. Gynaecol. Oncol. 2006, 27(4), 337–344;
Published: 10 August 2006
Abstract

Human genital papillomaviruses are the necessary cause of cervical cancer. A prophylactic vaccine designed to prevent genital HPV disease by inducing virus neutralizing antibodies has been proposed. Studies on animal models have produced relevant data on the efficacy of HPV vaccine. The results of HPV clinical studies suggest that it will be possible to develop an effective vaccine. Nevertheless the number of subjects analyzed in the full text published clinical studies is still poor. Although a recently presented phase III study appears satisfied, it is probably necessary for a larger phase III study. Besides the choice of the geographical area for a very large clinical trial, there are different aspects to consider, such as the identification of the target population, identification of the endpoints, composition of the vaccine and marketing of the vaccine. Furthermore there are two open questions: the duration of protection and the behavioral modifications. All these issues are discussed in this review.

Keywords
Papillomavirus
Cervical Cancer
Vaccination
Share
Back to top